Bluebird Bio Price to Book Ratio 2012-2021 | BLUE

Historical price to book ratio values for Bluebird Bio (BLUE) over the last 10 years. The current price to book ratio for Bluebird Bio as of October 15, 2021 is 1.43.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Bluebird Bio Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 20.90 1.43
2021-06-30 31.98 $14.58 2.19
2021-03-31 30.15 $17.80 1.69
2020-12-31 43.27 $20.40 2.12
2020-09-30 53.95 $22.96 2.35
2020-06-30 61.04 $25.41 2.40
2020-03-31 45.96 $20.14 2.28
2019-12-31 87.75 $23.21 3.78
2019-09-30 91.82 $26.60 3.45
2019-06-30 127.20 $29.63 4.29
2019-03-31 157.33 $32.18 4.89
2018-12-31 99.20 $34.44 2.88
2018-09-30 146.00 $36.59 3.99
2018-06-30 156.95 $29.02 5.41
2018-03-31 170.75 $31.36 5.44
2017-12-31 178.10 $32.86 5.42
2017-09-30 137.35 $24.93 5.51
2017-06-30 105.05 $26.35 3.99
2017-03-31 90.90 $19.92 4.56
2016-12-31 61.70 $21.37 2.89
2016-09-30 67.78 $18.62 3.64
2016-06-30 43.29 $20.52 2.11
2016-03-31 42.50 $21.83 1.95
2015-12-31 64.22 $23.05 2.79
2015-09-30 85.55 $24.26 3.53
2015-06-30 168.37 $25.56 6.59
2015-03-31 120.77 $14.51 8.32
2014-12-31 91.72 $15.19 6.04
2014-09-30 35.88 $9.12 3.93
2014-06-30 38.57 $6.61 5.84
2014-03-31 22.74 $5.94 3.83
2013-12-31 20.98 $6.34 3.31
2013-09-30 26.96 $6.67 4.04
2013-06-30 24.97 $6.83 3.65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.412B $0.251B
Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00